CPT code 96402 denotes the clinical procedure of administering a hormonal anti‑neoplastic drug via subcutaneous or intramuscular injection. This code captures parenteral delivery of systemic hormonal therapy outside of intravenous infusion, and it is used across ambulatory oncology and outpatient practice settings. Accurate use of this code is important for coding consistency, clinical documentation, and payer processing for injectable hormonal cancer treatments.

Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for this administration route, typical sites of service, and the implications for claims coding. The publication also covers payer-specific coverage patterns, common billing modifiers encountered with injectable oncology services, and benchmarks for utilization where available.

This summary provides clinicians, coders, and billing professionals with the necessary context to identify when 96402 is appropriate, understand where the service is typically rendered, and what to expect from major national payers. Data not available in the input are noted where applicable, and the content focuses on national-level relevance rather than state-specific policy.